ESTRO 2022 - Abstract Book

Debate This house believes that an intensive follow up for high-risk breast cancer patients should be considered. ......... (abs. 848 - 853) Symposium Challenging the traditional margins for microscopic diseases.....................................................................(abs. 854 - 857) Adapting to changes on different time scales................................................................................................(abs. 858 - 861) Debate This house believes that brachytherapy is a dying art. .................................................................................(abs. 862 - 867) Symposium Mobility for radiation oncology professionals................................................................................................(abs. 868 - 874) Mini-Oral 21: Radiomics & modelling...............................................................................................................................(abs. 875 - 882) 22: AI, big data, automation. ............................................................................................................................(abs. 883 - 890) Poster Discussion 21: Implementation of new technology & techniques...................................................................................(abs. 891 - 902) 22: Gynaecological.............................................................................................................................................(abs. 903 - 914) Award Lecture K Breur Award....................................................................................................................................................(abs. 915 - 916) Donal Hollywood Award. ........................................................................................................................................... (abs. 917) Proffered Papers Health economics..............................................................................................................................................(abs. 918 - 923) CNS......................................................................................................................................................................(abs. 924 - 929) Breast..................................................................................................................................................................(abs. 930 - 935) Multicentre validation studies..........................................................................................................................(abs. 936 - 941) Inter-fraction motion and adaptive radiotherapy..........................................................................................(abs. 942 - 947) Dosimetry & treatment planning.....................................................................................................................(abs. 948 - 953)